NHS under Labour carries out 100,000 more appointments a week than under Tories
Health Secretary Wes Streeting says 'every extra appointment we've delivered represents someone getting their life back on track'
The NHS in England is carrying out 100,000 more appointments a week now than it was under the previous Tory government.
Health Secretary Wes Streeting announced an extra 4.2 million appointments took place in the first nine months since the General Election when compared to the same period the previous year. This more than double the target Labour had set to deliver two million extra NHS appointments in the first year. Mr Streeting said: 'Every extra appointment we've delivered represents someone getting their life back on track. A parent no longer in pain, a worker returning to their job, an elderly person regaining their independence.
'What's remarkable is that we're seeing progress faster than expected. We've delivered 4.2 million extra elective appointments in the nine months since July – more than double our target of two million in the first year.
"This didn't happen by accident. With proper investment and proper reform, we're changing how care is delivered.'
The NHS waiting list in England has come down to its lowest for two years but still stood at 7.39 million treatments waiting to be carried out at the end of April
New NHS data also shows 6,700 more mental health workers have now been recruited since July 2024. This is 79% of the way to the Government's 8,500 target.
Mr Streeting said: 'Not getting the right support for your mental health isn't just debilitating, it can hit a painful pause button on your life – stopping you working, enjoying time with family and friends, or living day-to-day life. Patients have faced the crisis of access to mental health services for far too long.
'We are already over halfway towards our target of recruiting 8,500 extra mental health workers, and through our upcoming 10 Year Health Plan we will get more people back to health and back to work.'
Since last year's General Election the incoming Labour government has increased NHS spending by £26 billion and ended NHS strikes which had been hampering the service after a decade-long funding squeeze under the Tories.
Mr Streeting added: 'When there's so much cynicism in politics going round, I'm proud that this is a government that delivers on its promises. We promised to cut NHS waiting lists, and we're delivering. We said we'd hire 1,000 new GPs, and we've recruited over 1,500. We pledged to make our NHS fit for the future and we've invested £26 billion just this year to start making that a reality.
'We're bringing services closer to communities, giving patients more control over their treatment and boosting digital innovations so the NHS works better for everyone.
'The journey to getting our NHS back on its feet will take time, but these early results show we're on the right path. It's only this government that can be trusted to rebuild our NHS and make it fit for the future.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Record
an hour ago
- Daily Record
Weight loss jabs won't help you shift the pounds if you're still doing these things
With Mounjaro being rolled out at GPs down south, experts have listed the reasons why people getting the jabs may still not lose weight As the NHS down south begins rolling out weight-loss injections through GPs, demand is expected to rise sharply. However, with only around 220,000 patients eligible over the next three years, access may not be as easy as many expect. One particular injectable drawing significant notice and media coverage is Mounjaro, or Tirzepatide, to give it its medical name, initially developed for the management of type 2 diabetes. The medication has been licensed in the UK for obesity treatment since November 2024, earning acclaim for its effectiveness in facilitating substantial weight loss. Other injectable treatments include Wegovy and Nevolat. "While Mounjaro is an effective medication for weight loss, it's normal to encounter a plateau at some point," Dr. Crystal Wyllie at ZAVA explained. "With the NHS rollout still limited, many people won't qualify straight away, so understanding your full range of options is crucial.... working closely with your doctor is key to finding the safest and most personalised approach." As Mounjaro becomes more widely available, experts at ZAVA want to remind users what to expect, why it might not always work as expected, and how to avoid common setbacks. Incorrect medication use or dosage Mounjaro's effectiveness often increases as you move up the dosage ladder, ZAVA healthcare providers advise. The medication is typically titrated slowly to reduce side effects, eventually reaching maintenance doses of up to 15mg per week. If you're still on a lower dose or haven't advanced as recommended, your weight loss may be limited. Consistency is crucial. Skipping doses, delaying titration, or not following your provider's schedule can reduce the medication's impact. Many people don't feel the full effect until 8–12 weeks in, so patience and adherence are key. You should give Mounjaro at least three months before judging its effectiveness. If you're experiencing side effects, it's absolutely fine to remain at a lower dose for longer. Step up more slowly if you're not tolerating side effects well, there's no need to push through discomfort. You can always increase the dose later once your body has adjusted. Comfort and tolerability are just as important as consistency for long-term success. Poor diet and lack of exercise Weight loss jabs don't override the fundamental rule of weight loss - you must burn more calories than you consume. Even with a smaller appetite, eating more than your body needs will still cause progress to stall. Healthy diet tips: Be strict with calorie tracking until portion control becomes second nature Aim for a calorie daily deficit to lose weight steadily Prioritise whole foods over high-sugar, high-fat processed options Follow a diet tailored to your needs, and explore healthy recipe ideas to stay on track Stay hydrated and limit alcohol Stress and sleep issues Chronic stress and poor sleep are major weight loss blockers. Stress increases cortisol, a hormone linked to fat retention, especially around the abdomen. Sleep deprivation increases ghrelin (hunger hormone) and decreases leptin (fullness hormone), making you more likely to overeat and less likely to move. You're also more impulsive and less motivated when sleep-deprived, making it harder to stick to your diet and exercise routine. Prioritise stress management techniques (like mindfulness or journaling), and aim for 7-9 hours of sleep per night. Health conditions and medications Medical issues such as PCOS, diabetes, hypothyroidism, or insulin resistance can all interfere with weight loss. Similarly, certain medications (like antidepressants or steroids) may cause weight gain or inhibit fat loss. If weight loss stalls despite doing everything right, consult your GP to rule out or address any underlying conditions. If you have a known medical condition, keep on top of your routine reviews and inform your GP or specialist about any weight loss treatments you're using. Follow-up helps ensure your treatment plan remains safe and effective. Unrealistic expectations Weight loss is a long-term process. Initial drops (often water weight) can be misleading. Progress will slow, and that's okay. Avoid comparing yourself to others or obsessively checking the scale. Focus on consistency, not speed. Your journey is unique, and sustainable weight loss takes time. Lack of support Motivation by itself often isn't enough. Without support from those who understand your goals, the journey can feel lonely and overwhelming. Lean on friends and family who encourage you. Join online communities or local support groups, including NHS-recommended programs. Consider working with a dietitian or coach for personalised guidance and accountability Before beginning any weight loss treatment, please consult your GP or healthcare professional. These treatments may not be suitable for everyone. Join the Daily Record WhatsApp community! Get the latest news sent straight to your messages by joining our WhatsApp community today. You'll receive daily updates on breaking news as well as the top headlines across Scotland. No one will be able to see who is signed up and no one can send messages except the Daily Record team. All you have to do is click here if you're on mobile, select 'Join Community' and you're in! If you're on a desktop, simply scan the QR code above with your phone and click 'Join Community'. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. To leave our community click on the name at the top of your screen and choose 'exit group'.
Daily Record
an hour ago
- Daily Record
Scientists name food that turns calories into muscle, not fat
The study found that it 'redirected surplus calories to muscle growth instead of fat storage' Scientists have revealed that a simple compound found in food can influence whether your body converts calories into 'fat or muscle'. Zest Science, which provides health advice 'developed alongside leading researchers and medical doctors', was referring to a 2024 study about Vitamin D. On its Instagram page, Zest Science stated that a deficiency in Vitamin D could lead to fatigue, mood swings, muscle weakness, and poor recovery. Astonishingly, up to half of the world's population suffers from a lack of Vitamin D. They even suggest that you 'could be doing everything right' in terms of exercise, but a lack of Vitamin D could be sabotaging your training. The scientists stated: "Vitamin D decides if the calories you eat turn to fat or muscle. A 2024 study found that Vitamin D redirected surplus calories to muscle growth instead of fat storage. "High doses of Vitamin D caused a hormonal shift, altering how calories were utilised. They suppressed myostatin - a hormone that blocks muscle growth - increased leptin sensitivity - improving fat metabolism - and boosted resting energy expenditure without changes in food intake or activity. "Up to 50 per cent of the world's population is Vitamin D deficient. Symptoms include fatigue, mood swings, poor recovery, and muscle weakness. A deficiency equals muscle loss, fat gain, and higher disease risk." How to consume Vitamin D The NHS has emphasised the importance of Vitamin D in regulating the levels of calcium and phosphate in our bodies, which are crucial for maintaining healthy bones, teeth, and muscles. A deficiency in Vitamin D can lead to serious health issues such as rickets and other bone deformities. In adults, it can result in bone pain due to a condition known as osteomalacia. The Government's advice is that everyone should consider taking a daily vitamin D supplement during the autumn and winter months, as sunlight is typically the primary source of this vital nutrient. However, there are also numerous foods rich in Vitamin D. These include oily fish like salmon, sardines, trout, herrings, and kippers. Red meat, particularly beef liver, is another good source, as are eggs, especially the yolks, and canned tuna. Zest scientists have warned: "You could be doing everything still struggling with fatigue, slow recovery, and stubborn body fat." They added that optimising Vitamin D levels won't solve all problems, but if you're deficient, it could reduce body fat storage, support muscle growth, and boost your metabolism. "Vitamin D deficiency is sneaky - and shockingly common. Symptoms are easy to dismiss."
ITV News
2 hours ago
- ITV News
‘Life-changing' drug for Norfolk teenager who lost mother, aunt and uncle to condition
A teenager who lost her mother, aunt and uncle to a genetic condition has become the first person in Europe to receive a 'life-changing' drug after it was approved for use on the NHS. Mary Catchpole, 19, from Norfolk suffers from activated PI3-Kinase delta syndrome (APDS), a rare inherited disorder that leaves people with a significantly weakened immune system. Patients with APDS are vulnerable to repeated infections and face a lifetime of antibiotics and invasive procedures to try and keep them well. Miss Catchpole's mother's side of the family has been badly affected by APDS – her mother Sarah died aged 43 in 2018, while her aunt Helen died aged 12, her uncle Edward when he was 39 and her grandmother Mary when she was 48. Now, thanks to researchers in Cambridge who identified APDS, Miss Catchpole has received a new drug to treat it at Addenbrooke's Hospital in Cambridge. The medicine, called leniolisib (Joenja), is the first ever targeted treatment for APDS and is a simple tablet taken twice a day. Miss Catchpole is a teaching assistant who lives in Great Yarmouth with her father Jimmy, 64, and brother Joe, 20, who does not have the condition. She told the PA news agency: 'I was diagnosed with APDS aged seven and it's had a big effect on my life. 'I had lots of cannulas when I was younger and lots of hospital trips. 'I had a permanent line in the side of my body when I was younger which they put medicine in regularly at the hospital. 'I wasn't allowed to do very much physical activity so I had to sit out a lot in PE at school. 'I used to be called an attention-seeker because obviously it was hidden, so no-one really believed me. 'It also stopped me from doing a lot of my dancing, which I've always loved to do. So it has been hard.' Miss Catchpole said taking the new drug is 'life-changing' as it means she can leave behind huge amounts of medication. She added: 'I feel really blessed because it's so simple to do and it doesn't take up very much time, whereas for the medication, it just takes such a long time to do. 'So it's really a blessing, but it's also obviously bittersweet because my late family members never got the chance to have it.' APDS was identified by Cambridge researchers in 2013, with Miss Catchpole's family playing a key role in its discovery. Her mother and uncle were Addenbrooke's patients and were offered DNA sequencing to see if there was a genetic cause for their immunodeficiency. Researchers identified a change in their genes that increased activity of an enzyme called PI3-Kinase delta – meaning this enzyme is effectively 'switched on' all the time. This prevents immune cells from fighting infection and leads to an abnormal immune function. The new drug works by inhibiting the enzyme, effectively normalising the immune system. Now, Miss Catchpole says she can look to the future with optimism and is excited to lead a normal life. 'I really want to become a dance teacher,' she said. 'I absolutely love my current job as a teaching assistant but I'd also like to go on some adventures as well. 'I've always felt different so it will be nice to feel like I belong. 'When I had sleepovers when I was younger and had to take all my medication with me, I didn't feel like a normal child. 'To be able to feel normal going about my day-to-day life is going to be really nice.' Until now, the only treatments for APDS patients were antibiotics for infections, immunoglobulin replacement therapy to prevent infections and organ damage, and a bone marrow or stem cell transplant. Dr Anita Chandra, consultant immunologist at Addenbrooke's and affiliated assistant professor at the University of Cambridge, said: 'It is incredible to go from the discovery of a new disease in Cambridge to a treatment being approved and offered on the NHS within the space of 12 years. 'This new drug will make a huge difference to people living with APDS.' Professor Sergey Nejentsev, from the University of Cambridge who led the research that discovered APDS, said: 'As soon as we understood the cause of APDS, we immediately realised that certain drugs could be used to inhibit the enzyme that is activated in these patients. 'Leniolisib does precisely that. I am delighted that we finally have a treatment which will change the lives of APDS patients.' Professor James Palmer, NHS England's medical director for specialised commissioning, said: 'We're delighted to see Mary become the first patient in Europe to receive this first ever targeted and approved therapy for a rare condition identified just over a decade ago – in Cambridge no less. 'This treatment could be life-changing for those affected by this debilitating genetic disorder, and this important step forward is another example of the NHS's commitment to offering access to innovative medicines for those living with rare conditions.' Experts believe the drug will work long-term in patients as long as they keep taking the tablets. Researchers are now looking at the potential for leniolisib to work on other, more common immune conditions. Patients eligible for leniolisib can be referred to Addenbrooke's for specialist review and care. Between 40 to 50 people in England are known to have APDS. The list price for leniolisib is £352,000 per person per year but the company Pharming has agreed a discount for the NHS. The team that discovered APDS included researchers from the University of Cambridge, Babraham Institute, Medical Research Council (MRC) Laboratory for Molecular Biology, and Addenbrooke's, with funding from Wellcome and the National Institute for Health and Care Research (NIHR).
